<DOC>
	<DOCNO>NCT02576041</DOCNO>
	<brief_summary>The aim study evaluate effect Bilastine patient ' attention reactivity level measure psychophysical performance F1-high speed simulator drive test .</brief_summary>
	<brief_title>Effects Bilastine F1 Simulator Driving Performance Patients Affected Allergic Rhinitis and/or Urticaria</brief_title>
	<detailed_description>This phase IV , interventional , prospective , mono-centric , single arm , uncontrolled , open label trial . The study include outpatient affect Allergic Rhinitis and/or Chronic Urticaria , respond inclusive criterion able perform preliminary drive test F1-high speed simulator ( simulator centre ) without experience sign symptom intolerance towards drive simulation ( e.g. , nausea , vomit dizziness etc ) . Each subject underwent 3 ambulatory visit hospital site 3 drive test simulator centre .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Urticaria</mesh_term>
	<criteria>Patients affect allergic rhinitis ( seasonal perennial ) urticaria ( induced induce ) need histamine H1receptor antagonist therapy accord PI therapeutic decision ; Males females age 21 55 year ; Body Mass Index ( BMI ) 19 30 kg/m2 ( include ) ; If woman : negative pregnant test contraception least 30 day study ( Visit V1 ) end study . For woman patient negative pregnant test acquire Simulator performance ( Visit V1H ) ; Subjects valid drive license 3 year ; Subjects drive experience least 5000 km per year ; Subjects able understand protocol come visit ; Subjects able give write informed consent ; Subjects , investigator 's judgment , likely compliant study use potentially adulterate drug ; Potential compliant subject enrol tolerate driving F1simulator ( start V1 S ) . Subjects autoimmune urticaria ; Hypersensitivity active substance bilastine excipients ; History symptom severe mental physical disorder take substance alcohol ; Excessive smoking ( 20 cigarette per day ) , consumption caffeinated beverage ( 6 cup per day ) ; Subjects need unimpaired psychophysical condition due job ; Subjects non correct visual defect locomotor disorder could interfere study ; Subjects ineligible Visit V1 ; Subjects know allergic reaction antihistamine ; Subjects porphyria ; Subjects important sleep disturbance kinetosis ; Subjects clinically important ( base Investigator 's judgment ) renal hepatic impairment , gastrointestinal disease ( e.g . malabsorption ) ; Subjects medical history seizure ( i.e . epileptic relate ) current seizure ; Presence significant medical condition/concomitant illness , opinion Investigator , render patient immunocompromised suitable clinical trial could adversely affect subject 's participation evaluation study ; Subjects , opinion Investigator , concern compliance study procedure ; Presence permanent gastrointestinal condition may influence oral therapy ( chronic diarrhoea disease , congenital malformation surgical mutilation gastrointestinal tract ) ; Presence active cancer require chemotherapy radiation therapy ; Presence alcohol abuse drug addiction ; Pregnancy breastfeeding ; Treatment : diuretic , corticosteroid ( medication apply topically ) , central nervous system medication medication sedative effect ( sleep inducing antidepressant , sedative medication ) , medication interact bilastine , medication . In particular , patient treat follow drug exclude : Imipramine antidepressant , anticholinergic antiparkinsonians , atropine antispasmodic , disopyramide , phenothiazine neuroleptic ; Sedative antidepressant , monoamine oxidase ( MAOI ) inhibitor , barbiturate , benzodiazepine , clonidine related substance , hypnotic , morphine derivative ( analgesic , antitussive , replacement treatment ) , neuroleptic , anxiolytic ; Treatments Pglycoprotein inhibitor ( e.g . ketoconazole , erythromycin , cyclosporine , ritonavir , diltiazem ) , may increase plasmatic level bilastine ; Treatments substrates inhibitor OATP1A2 ( e.g . ritonavir , rifampicin ) , may decrease plasma concentration bilastine Other treatment interact bilastine ( e.g . ketoconazole , erythromycin , diltiazem ) ; Treatment anticoagulant ( e.g . warfarin ) ; Sedatives , hypnotic , tranquillizer addictive agent ; Other treatment admit study : betahistine , anticholinesterase , arrhythmogenic drug ; H2antihistamines ; H1 antihistamine study medication rescue medication . In case , possibility inclusion patient take drug leave Investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>drive simulator</keyword>
</DOC>